|
1.Zhang YH#, Xie R#, Dai CS, Gao HW, Zhou G, Qi TT, Wang WY, Wang H*, Cui YM*. Thyroid hormone receptor-beta agonist HSK31679
alleviates MASLD by modulating gut microbial sphingolipids. J Hepatol. 2025 Feb;82(2):189-202.
2.Qian J, Xie Y, Mao Q, Xie Q, Gu Y, Chen X, Hu G, Yang Y, Lu J, Zou G, Zhang Q, Fu L, Chen Y, Guo X, Hou J, Yan Y, Wu JJ*, Cui Y*,
Wang G*. A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic
hepatitis B who are HBeAg-negative. Hepatology. 2025 Apr 1;81(4):1328-1342.
3.Sun X#, Zhang J#, Dong B#, Xiong Q#, Wang X, Gu Y, Wang Z, Liu H, Zhang J, He X, Liu H, Zhong Y, Yi C, Chi X, Liu Z*, Pang X*,
Cui Y*. Targeting SLITRK4 Restrains Proliferation and Liver Metastasis in Colorectal Cancer via Regulating PI3K/AKT/NFκB Pathway
and Tumor-Associated Macrophage. Adv Sci (Weinh). 2025 Jan;12(1):e2400367.
4.Guo P, Wang W, Xiang Q, Pan C, Qiu Y, Li T, Wang D, Ouyang J, Jia R, Shi M, Wang Y, LiJ, Zou J, Zhong Y, Zhao J, Zheng D, Cui Y*,
Ma G*, Wei W*. Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis.
Cell Host Microbe. 2024 Sep 11;32(9):1502-1518.e9.
5.Dong B#, Gu Y#, Sun X#, Wang X, Zhou Y, Rong Z, Zhang J, Shi X, Zhang Z, He X, Chen L, Xiong Q*, Pang X*, Cui Y*. Targeting TUBB3
Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer[J]. Adv Healthc Mater. 2024: e2400673.
6.Pang X#, Sun X#, Gu Y#, He X, Gong K, Song S, Zhang J, Xia J, Liu Z*, Cui Y*. Discovery of C19-9 as a novel non-RGD inhibitor of
alphavbeta3 to overcome enzalutamide resistance in castration-resistant prostate cancer[J]. Signal Transduct Target Ther. 2023, 8(1): 60.
7.Wang G#, Zhao K#, Han J#, Hu Z#, Zhang T, Wang Y, Shi R, Li Y, Song Q, Du H, He P, Xu S, Yang X, Fu Y, Cui Y*, Xie L*. Safety and
immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded,
placebo-controlled, phase I clinical trial[J]. J Infect. 2023, 86(2): 154-225.
8.Xiang Q#, Wang Z, Mu G, Xie Q, Liu Z, Zhou S, Zhang H, Wang Z, Jiang J, Hu K, Zhang Y, Zhao Z, Yuan D, Guo L, Wu T, Zhang J, Wang N,
Xiang J, Gu Z, Sun J, Cui Y*. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with
nonvalvular atrial fibrillation: A multicentre prospective cohort study[J]. Clin Transl Med. 2023, 13(5): e1263.
9.Xiang Q#, Xie Q#, Liu Z, Mu G, Zhang H, Zhou S, Wang Z, Wang Z, Zhang Y, Zhao Z, Yuan D, Guo L, Wang N, Xiang J, Song H, Sun J,
Jiang J, Cui Y*. Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular
atrial fibrillation: A nationwide multicentre prospective cohort study[J]. Clin Transl Med. 2022, 12(12): e1104.
10.Fu L, Jia G, Liu Z, Pang X, Cui Y*. The applications and advances of artificial intelligence in drug regulation:
A global perspective. Acta Pharm Sin B. 2025 Jan;15(1):1-14.
11.Pang X#, He X#, Qiu Z#, Zhang H#, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q*, Cui Y*. Targeting integrin pathways:
mechanisms and advances in therapy[J]. Signal Transduct Target Ther. 2023, 8(1): 1.
12.Zhang YH, Wang WY, Cui YM*. Gut Microbiome Metabolism Drives the Resolution of Patients With Coronavirus Disease 2019[J].
Gastroenterology. 2022, 163(1): 336-37.
13.Ji X, Meng X, Zhu X, He Q, Cui Y*. Research and development of Chinese anti-COVID-19 drugs[J]. Acta Pharm Sin B. 2022, 12(12): 4271-86.
14.Su X, Wang H, Zhao N, Wang T*, Cui Y*. Trends in innovative drug development in China[J]. Nat Rev Drug Discov. 2022, 21(10): 709-10.
|
